None listed
Conditions
Interventions
None listed
Sponsors
Korea Institute of Oriental Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Patients diagnosed with stage IIIB, IIIC, IV (TNM 8th edition) non-small cell lung cancer 2. Patients scheduled to be treated for immune checkpoint inhibitor (Pembrolizumab, Atezolizumab) monotherapy for secondary or higher line therapy after platinum-based primary therapy has been failed 3. Patients over 6 months survival expected 4. Patients with ECOG scale (ECOG-PS) 0-2 5. Patients who voluntarily participate to this clinical study with written informed consent
Exclusion criteria
Exclusion criteria: 1. Patients having active brain metastases with clinically significant neurological symptoms or signs 2. Patients diagnosed with other malignancies within 5 years which may influence non-small cell lung cancer 3. Patients having autoimmune disease 4. Pregnant woman or lactating woman 5. Patients considered to be unsuitable to participate in this study by the investigators
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Progression-Free Survival (PFS) | — |
Secondary
| Measure | Time frame |
|---|---|
| Overall Response Rate (ORR);Complete Response (CR) rate;Overall Survival (OS);Time To Response (TTR);Time to Tumor Progression (TTP);European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core questionnaire (EORTC QLQ-C30);European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Lung cancer 13 (EORTC QLQ-LC13);Adverse events;Immune assessment test (Blood) | — |
Countries
Korea, Republic of
Contacts
Public ContactMi-kyung Jeong
Korea Institute of Oriental Medicine
Outcome results
None listed